Posted by Michael Wonder on 09 Mar 2021
Seqirus announces U.S. FDA approval of expanded age indication of its cell based quadrivalent influenza vaccine for people two years of age and older
5 March 2021 - Seqirus today announced that the U.S. FDA has approved Flucelvax Quadrivalent (influenza vaccine), the company's cell-based quadrivalent influenza vaccine for an expanded age indication for people two years of age and older.
Flucelvax Quadrivalent was previously FDA approved for use in persons four years of age and older. Flucelvax Quadrivalent will be available as a 0.5 mL intramuscular vaccine per dose for the 2021/22 U.S. influenza season.
